Small interfering RNA against PTTG: a novel therapy for ovarian cancer

Shahenda M El-Naggar1, Mohammed T Malik, Sham S Kakar

  • 1Department of Medicine, and the James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.

Insights

Silencing the pituitary tumor transforming gene (PTTG) with siRNA reduced ovarian cancer cell proliferation and tumor growth in mice. These findings highlight PTTG as a potential target for new ovarian cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian epithelial cancer is a leading cause of female cancer deaths, with limited detection methods and chemotherapy resistance posing significant challenges.
  • High expression of the pituitary tumor transforming gene (PTTG) is observed in various tumors, including ovarian cancer, and is linked to cellular transformation and tumor formation.

Purpose of the Study:

  • To investigate the correlation between PTTG expression levels and ovarian tumorigenesis.
  • To determine if down-regulating PTTG can suppress tumor growth in ovarian cancer models.

Main Methods:

  • Small interfering RNA (siRNA) was used to silence PTTG expression in human A2780 ovarian carcinoma cells.
  • The effects of PTTG silencing on cell proliferation, colony formation in soft agar, and tumor development in nude mice were assessed.

Main Results:

  • PTTG siRNA effectively reduced PTTG expression at both mRNA and protein levels.
  • A 50% reduction in cell proliferation and a 70% decrease in soft agar colony formation were observed in cells with silenced PTTG.
  • Tumor incidence and growth were significantly decreased in nude mice injected with PTTG-silenced A2780 cells.

Conclusions:

  • PTTG plays a crucial role in ovarian tumorigenesis.
  • Down-regulation of PTTG significantly inhibits ovarian cancer cell growth and tumor development.
  • PTTG represents a promising molecular target for developing novel ovarian cancer therapies.

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
piRNA - Piwi-interacting RNAs02:57

piRNA - Piwi-interacting RNAs

PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...